Results 161 to 170 of about 88,800 (280)
Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)
The Prostate, Volume 86, Issue 6, Page 697-709, May 2026.ABSTRACT Background
Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector pathways. Patients and Methods
E2809 assigned 108 high‐risk BCR patients (1:1, arm‐A: arm‐B) to two phases with 4‐week cycles ...Anna C. Ferrari, Yu‐Hui Chen, Ronald Rodríguez, Gary R. Hudes, Emmanuel S. Antonarakis, Noah M. Hahn, Hilary Ma, Elizabeth R. Plimack, Tina Mayer, Bradley C. Carthon, Glenn Liu, Michael A. Carducci, Robert DiPaola +12 morewiley +1 more sourceOne year in: early European adoption of the da Vinci Single Port platform—a multi‐institutional study from the European Association of Urology Robotic Urology Section Scientific Working Group
BJU International, Volume 137, Issue 6, Page 975-978, June 2026.Francesco Pellegrino, Antony Pellegrino, Ugo Giovanni Falagario, Marco Tozzi, Robin Weston, Vishwanath Hanchanale, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Gabriele Tuderti, Aldo Brassetti, Giuseppe Simone, Alessandro Izzo, Gianluca Spena, Roberto Contieri, Sisto Perdonà, Alessandro Tedde, Massimo Madonia, Stefano Tappero, Elio Mazzone, Paolo Dell'Oglio, Antonio Galfano, Karel Decaestecker, Peter Dekuyper, Filip Ameye, Federico Lavagno, Giancarlo Marra, Paolo Gontero, Carlo Costi, Giovanni Passaretti, Antonio Russo, Franco Gaboardi, Axel Möller, Fredrik Sundquist, Mats Olsson, Chiara Vaccaro, Francesco Alessandro Mistretta, Stefano Luzzago, Gennaro Musi, Andrea Piccolini, Marco Paciotti, Giovanni Lughezzani, Nicolò Maria Buffi, Enrico Checcucci, Paolo Alessio, Daniele Amparore, Francesco Porpiglia, Filippo Marino, Luca Di Gianfrancesco, Davide De Marchi, Angelo Porreca, Christian Fankhauser, Matteo Ferro, Alberto Breda, Simone Crivellaro, Peter Wiklund, on behalf of the ERUS Scientific Working Group +56 morewiley +1 more sourceTreatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation
The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.ABSTRACT Background
Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo +12 morewiley +1 more sourcePatient‐side performance metrics and errors in robotic surgery: Junior‐ European Association of Urology Robotic Urology Section/Young Academic Urologists (J‐ERUS/YAU) construct validation
BJU International, Volume 137, Issue 6, Page 938-940, June 2026.Christoph Würnschimmel, Malte Boese, Razvan Ognean, Marco Paciotti, Mike Wenzel, Carlo Andrea Bravi, Ruben De Groote, Paolo Dell'Oglio, Fabrizio Di Maida, Marcio Covas Moschovas, Federico Piramide, Filippo Turri, Gabriele Sorce, Nikolaos Liakos, Anthony Gallagher, Domenico Veneziano, Ton Brouwers, Markus Graefen, Evangelos Liatsikos, Alberto Breda, Alessandro Larcher, Iulia Andras +21 morewiley +1 more sourceExternal Validation of the Martini‐Klinik Nomogram Predicting the Indication for Adjuvant Radiation Therapy According to EAU Guidelines Among Patients With High‐Risk Prostate Cancer After Radical Prostatectomy
The Prostate, Volume 86, Issue 6, Page 710-717, May 2026.ABSTRACT Objective
To externally validate the Martini‐Klinik nomogram based on patient and clinical tumor characteristics predicting the indication for adjuvant radiation therapy after radical prostatectomy according to guideline recommendations of the European Association of Urology (EAU) in high‐risk prostate cancer patients treated with radical ...Carolin Siech, Tonio Brüggemann, Quynh Chi Le, Benedikt Lauer, Clara Humke, Felix Preisser, Tobias Maurer, Maximilian Kriegmair, Markus Graefen, Thomas Steuber, Mike Wenzel, Felix K. H. Chun, Philipp Mandel +12 morewiley +1 more source[18F] PSMA PET‐CT and [18F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests
The Prostate, Volume 86, Issue 7, Page 800-804, May 15, 2026.ABSTRACT Background
To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods
An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...M. A. Tárraga‐Honrubia, A. S. Salinas‐Sánchez, S. Navarro‐Jiménez, M. V. Lorenzo‐Sánchez, P. Carrión‐López, J. M. Giménez‐Bachs +5 morewiley +1 more sourceIncidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy. [PDF]
CancerLane BR, Lewicki P, Noyes SL, Labardee C, Meah S, Daignault-Newton S, Hafron J, Morgan TM, Radhakrishnan A, Dess RT, Montie J, Ghani KR, Ginsburg KB, Borza T. +13 moreeuropepmc +1 more sourceIn the Era of mpMRI and PSMA PET/CT: Does Digital Rectal Examination Still Matter?
The Prostate, Volume 86, Issue 7, Page 805-810, May 15, 2026.ABSTRACT Background
With the increasing integration of multiparametric MRI (mpMRI) and 68Ga‐PSMA PET/CT into the diagnostic and staging algorithms of prostate cancer (PCa), digital rectal examination (DRE)—a once foundational and cost‐effective physical examination—has gradually become marginalized in daily clinical practice.Anil Eker, Fatih Diler, Selda Yilmaz Tatar, Ebru Hasbay, Cagatay Kayar, Berk Karaca, Mahmut Cinar, Yasin Ceylan, Deniz Bolat, Tansu Degirmenci, Serdar Celik +10 morewiley +1 more source